Cipher Pharmaceuticals, Inc. (CPH.TO)
14.17
+0.56
(+4.11%)
CAD |
TSX |
Nov 13, 16:00
Cipher Pharmaceuticals Enterprise Value : 336.68M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 336.68M |
| November 12, 2026 | 322.55M |
| November 11, 2026 | 325.32M |
| November 10, 2026 | 323.05M |
| November 09, 2026 | 326.08M |
| November 06, 2026 | 320.02M |
| November 05, 2026 | 315.23M |
| November 04, 2026 | 307.91M |
| November 03, 2026 | 308.92M |
| November 02, 2026 | 312.20M |
| October 30, 2026 | 308.42M |
| October 29, 2026 | 319.77M |
| October 28, 2026 | 319.77M |
| October 27, 2026 | 309.93M |
| October 26, 2026 | 314.98M |
| October 23, 2026 | 317.00M |
| October 22, 2026 | 323.56M |
| October 21, 2026 | 314.98M |
| October 20, 2026 | 313.46M |
| October 19, 2026 | 313.46M |
| October 16, 2026 | 313.46M |
| October 15, 2026 | 320.53M |
| October 14, 2026 | 315.99M |
| October 13, 2026 | 319.77M |
| October 09, 2026 | 323.56M |
| Date | Value |
|---|---|
| October 08, 2026 | 323.56M |
| October 07, 2026 | 323.81M |
| October 06, 2026 | 328.86M |
| October 05, 2026 | 324.82M |
| October 02, 2026 | 323.56M |
| October 01, 2026 | 323.56M |
| September 30, 2026 | 323.56M |
| September 29, 2026 | 335.53M |
| September 28, 2026 | 334.51M |
| September 25, 2026 | 340.61M |
| September 24, 2026 | 344.93M |
| September 23, 2026 | 350.27M |
| September 22, 2026 | 356.87M |
| September 21, 2026 | 354.08M |
| September 18, 2026 | 360.43M |
| September 17, 2026 | 365.26M |
| September 16, 2026 | 356.37M |
| September 15, 2026 | 357.64M |
| September 14, 2026 | 362.97M |
| September 11, 2026 | 351.03M |
| September 10, 2026 | 348.49M |
| September 09, 2026 | 349.50M |
| September 08, 2026 | 347.22M |
| September 04, 2026 | 352.05M |
| September 03, 2026 | 353.32M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| HLS Therapeutics, Inc. | 154.12M |
| Bausch Health Cos., Inc. | 31.74B |
| BioSyent, Inc. | 195.94M |
| Revive Therapeutics Ltd. | 6.520M |
| Knight Therapeutics, Inc. | 1.082B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 15.25M |
| Revenue (Quarterly) | 17.78M |
| Total Expenses (Quarterly) | 2.526M |
| EPS Diluted (Quarterly) | 0.5878 |
| Gross Profit Margin (Quarterly) | 67.42% |
| Profit Margin (Quarterly) | 85.80% |
| Earnings Yield | 12.99% |
| Operating Earnings Yield | 7.35% |
| Normalized Earnings Yield | 12.41 |